Clinical Trial Update: Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL [Phase 3]

View source ↗

Summary

This clinical trial update reports on the efficacy and safety of the Rituximab-based R-HAD regimen alone or in combination with Bortezomib in patients with rela…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• CYTARABINE (CYTARABINE)
• DEXAMETHASONE (Dexamethasone)
• Rituximab (rituximab)

Snippet

Sponsor: Prof. Dr. M. Dreyling (co-chairman) | Conditions: Mantle Cell Lymphoma | Phase 3 | Status: UNKNOWN